Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
March 14, 2023 07:30 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
March 09, 2023 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
February 02, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
January 31, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 08, 2022 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
November 03, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
September 06, 2022 08:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting
August 29, 2022 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 09, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
August 02, 2022 07:30 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...